LURASIDONE HYDROCHLORIDE | A212124 | MACLEODS PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
SUMITOMO DAINIPPON PHARMA CO., LTD. et al v. MACLEODS PHARMACEUTICALS LTD. et al 2 patentsANDA 212124lurasidone hydrochloride | D.N.J. | 2018-09-12 | Terminated 2019-01-14 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.4889
per ea
Lowest NADAC/Unit
$0.1348
per ea
Brand NDCs
0
Generic NDCs
9
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 33342042307LURASIDONE HCL 120 MG TABLET | $0.4889 | EA | Generic | — | 2026-06-17 |
| 72603062401LURASIDONE HCL 80 MG TABLET | $0.3366 | EA | Generic | — | 2026-06-17 |
| 33342042207LURASIDONE HCL 80 MG TABLET | $0.3366 | EA | Generic | — | 2026-06-17 |
| 33342042107LURASIDONE HCL 60 MG TABLET | $0.3018 | EA | Generic | — | 2026-06-17 |
| 72603062301LURASIDONE HCL 60 MG TABLET | $0.3018 | EA | Generic | — | 2026-06-17 |
| 72603062201LURASIDONE HCL 40 MG TABLET | $0.2232 | EA | Generic | — | 2026-06-17 |
Showing 6 of 9 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.